Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance
S Sunayama, Y Watanabe, H Ohmura, M Sawano… - Atherosclerosis, 1999 - Elsevier
Insulin resistance is associated with atherogenic lipoprotein phenotype, including small
dense LDL particle, hypertriglycemia and low HDL cholesterol levels. Troglitazone, a novel
insulin sensitizing agent, may improve the associated lipid profile in patients with insulin
resistance. We examined the effects of troglitazone (400 mg daily for 12 weeks) in 12 non-
diabetic coronary patients (60±10 years), all of whom had hyperinsulinemic response to an
oral glucose load. Troglitazone markedly reduced the insulin response. After the treatment …
dense LDL particle, hypertriglycemia and low HDL cholesterol levels. Troglitazone, a novel
insulin sensitizing agent, may improve the associated lipid profile in patients with insulin
resistance. We examined the effects of troglitazone (400 mg daily for 12 weeks) in 12 non-
diabetic coronary patients (60±10 years), all of whom had hyperinsulinemic response to an
oral glucose load. Troglitazone markedly reduced the insulin response. After the treatment …